The economic evaluation of ALS care: quality and cost

References

• Dang A, Likhar N, Alok U. Importance of economic evaluation in health care: an Indian perspective. Value Health Reg Issues. 2016;9:78–83.
   PubMedGoogle Scholar
• Edwards RT, McIntosh E. Applied health economics for public health practice and research [still image]. Oxford: Oxford University Press; 2019.
   Google Scholar
• Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. Value Health. 2019;22:377–82.
   PubMed Web of Science ®Google Scholar
• Schuller Y, Hollak CE, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis. 2015;10:92.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267:944–53.
   PubMed Web of Science ®Google Scholar
• Gajdos O, Rozanek M, Donin G, Kamensky V. Cost-utility analysis of home mechanical ventilation in patients with amyotrophic lateral sclerosis. Healthcare (Basel) 2021;9:142.
   PubMedGoogle Scholar
• Thakore NJ, Pioro EP, Udeh BL, Lapin BR, Katzan IL. A cost-effectiveness framework for amyotrophic lateral sclerosis, applied to riluzole. Value Health. 2020;23:1543–51.
   PubMed Web of Science ®Google Scholar
• Song H, Liu JC, Cao ZP, Luo WJ, Chen JY. Medical cost and healthcare utilization of amyotrophic lateral sclerosis in China: a cohort study based on hospital data from 2015 to 2018. Medicine (Baltimore). 2020;99:e23258.
   PubMed Web of Science ®Google Scholar
• Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240–5.
   PubMed Web of Science ®Google Scholar
• Gerkens S, Crott R, Cleemput I, Thissen JP, Closon MC, Horsmans Y, et al. Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity. Int J Technol Assess Health Care. 2008;24:318–25.
   PubMed Web of Science ®Google Scholar
• Sagili KD, Muniyandi M, Nilgiriwala KS, Shringarpure KS, Satyanarayana S, Kirubakaran R, et al. Cost-effectiveness of genexpert and LED-FM for diagnosis of pulmonary tuberculosis: a systematic review. PLoS One. 2018;13:e0205233.
   PubMed Web of Science ®Google Scholar
• Paganoni S, van de Rijn M, Drake K, Burke K, Doyle M, Ellrodt AS, et al. Adjusted cost analysis of video televisits for the care of people with amyotrophic lateral sclerosis. Muscle Nerve. 2019;60:147–54.
   PubMed Web of Science ®Google Scholar
• Oh J, An JW, Oh SI, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:202–8.
   PubMed Web of Science ®Google Scholar
• Schonfelder E, Osmanovic A, Muschen LH, Petri S, Schreiber-Katz O. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany. Orphanet J Rare Dis. 2020;15:149.
   PubMed Web of Science ®Google Scholar
• Lopes de Almeida JP, Pinto A, Pinto S, Ohana B, de Carvalho M. Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals. Amyotroph Lateral Scler. 2012;13:533–7.
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S, Becagli P, Zaccara G. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian cooperative group for the study of meta-analysis and the osservatorio SIFO Sui Farmaci. Pharmacoeconomics 1999;16:153–63.
   PubMed Web of Science ®Google Scholar
• Tavakoli M, Malek M. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J Neurol Sci 2001;191:95–102.
   PubMed Web of Science ®Google Scholar
• Ackerman SJ, Sullivan EM, Beusterien KM, Natter HM, Gelinas DF, Patrick DL. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics. 1999;15:179–95.
   PubMed Web of Science ®Google Scholar
• Darba J. Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: a population-based analysis. PLoS One 2019;14:e0223772.
   PubMed Web of Science ®Google Scholar
• van der Steen I, van den Berg JP, Buskens E, Lindeman E, van den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler. 2009;10:27–34.
   PubMed Web of Science ®Google Scholar
• Zwicker J, Qureshi D, Talarico R, Bourque P, Scott M, Chin-Yee N, et al. Dying of amyotrophic lateral sclerosis: health care use and cost in the last year of life. Neurology 2019;93:e2083–e93.
   PubMed Web of Science ®Google Scholar
• Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Maginnis K, Callas P, et al. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:119–27.
   PubMed Web of Science ®Google Scholar
• Connolly S, Heslin C, Mays I, Corr B, Normand C, Hardiman O. Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:58–62.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Lev B. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis. Pharmacoeconomics. 1997;12:578–84.
   PubMed Web of Science ®Google Scholar
• Obermann M, Lyon M. Financial cost of amyotrophic lateral sclerosis: a case study. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:54–7.
   PubMed Web of Science ®Google Scholar
• Lopez-Bastida J, Perestelo-Perez L, Monton-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009;10:237–43.
   PubMed Web of Science ®Google Scholar
• Gruis KL, Chernew ME, Brown DL. The cost-effectiveness of early noninvasive ventilation for ALS patients. BMC Health Serv Res 2005;5:58.
   PubMed Web of Science ®Google Scholar
• Meng L, Bian A, Jordan S, Wolff A, Shefner JM, Andrews J. Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:134–42.
   PubMed Web of Science ®Google Scholar
• Gray AM. ALS/MND and the perspective of health economics. J Neurol Sci 1998;160: S2–S5.
   PubMed Web of Science ®Google Scholar
• Lechtzin N, Wiener CM, Clawson L, Chaudhry V, Diette GB. Hospitalization in amyotrophic lateral sclerosis: causes, costs, and outcomes. Neurology 2001;56:753–7.
   PubMed Web of Science ®Google Scholar
• Galvin M, Ryan P, Maguire S, Heverin M, Madden C, Vajda A, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: a population- based study of consultations, interventions and costs. PLoS One. 2017;12:e0179796.
   PubMed Web of Science ®Google Scholar
• Athanasakis K, Kyriopoulos II, Sideris M, Rentzos M, Evdokimidis J, Kyriopoulos J. Investigating the economic burden of ALS in Greece: a cost-of-illness approach. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:63–4.
   PubMed Web of Science ®Google Scholar
• Corr B, Frost E, Traynor BJ, Hardiman O. Service provision for patients with ALS/MND: a cost-effective multidisciplinary approach. J Neurol Sci 1998;160: S141–S5.
   PubMed Web of Science ®Google Scholar
• Tejada RA, Malagon T, Franco EL. Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: a systematic review and meta-analysis. Vaccine 2022;40:2667–78.
   PubMed Web of Science ®Google Scholar
• Jensen CE, Jensen MB, Riis A, Petersen KD. Systematic review of the cost-effectiveness of implementing guidelines on low back pain management in primary care: is transferability to other countries possible? BMJ Open. 2016;6:e011042.
   PubMed Web of Science ®Google Scholar
• Caelers I, de Kunder SL, Rijkers K, van Hemert WLW, de Bie RA, Evers S, et al. Comparison of (Partial) economic evaluations of transforaminal lumbar interbody fusion (TLIF) versus Posterior lumbar interbody fusion (PLIF) in adults with lumbar spondylolisthesis: a systematic review. PLoS One. 2021;16:e0245963.
   PubMed Web of Science ®Google Scholar
• Lutz N, Clarys P, Koenig I, Deliens T, Taeymans J, Verhaeghe N. Health economic evaluations of interventions to increase physical activity and decrease sedentary behavior at the workplace: a systematic review. Scand J Work Environ Health. 2020;46:127–42.
   PubMed Web of Science ®Google Scholar
• Werbrouck A, Schmidt M, Putman K, Benhalima K, Verhaeghe N, Annemans L, et al. A systematic review on costs and cost-effectiveness of screening and prevention of type 2 diabetes in women with prior gestational diabetes: exploring uncharted territory. Diabetes Res Clin Pract. 2019;147:138–48.
   PubMed Web of Science ®Google Scholar
• Werbrouck A, Schmidt M, Putman K, Seghers J, Simoens S, Verhaeghe N, et al. Cost-effectiveness of exercise referral schemes: a systematic review of health economic studies. Eur J Public Health. 2022;32:87–94.
   PubMed Web of Science ®Google Scholar
• Wijnen BFM, van Mastrigt G, Evers S, Gershuni O, Lambrechts D, Majoie M, et al. A systematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia 2017;58:706–26.
   PubMed Web of Science ®Google Scholar
• Hamberg-van Reenen HH, Proper KI, van den Berg M. Worksite mental health interventions: a systematic review of economic evaluations. Occup Environ Med. 2012;69:837–45.
   PubMed Web of Science ®Google Scholar
• Vandepitte S, Alleman T, Nopens I, Baetens J, Coenen S, De Smedt D. Cost-effectiveness of COVID-19 policy measures: a systematic review. Value Health. 2021;24:1551–69.
   PubMed Web of Science ®Google Scholar